Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock Posted on January 19, 2024September 26, 2024 by KBD Admin
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older Posted on December 15, 2023September 26, 2024 by Kate Schykerynec
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche Posted on December 3, 2023September 26, 2024 by KBD Admin
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn Posted on November 28, 2023December 5, 2023 by KBD Admin
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa Posted on November 27, 2023November 28, 2023 by KBD Admin
Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To BDCA2 Modulator Antibody Portfolio From Centessa Pharmaceuticals Posted on November 27, 2023December 5, 2023 by KBD Admin
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan Posted on November 14, 2023November 14, 2023 by KBD Admin
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults Posted on November 1, 2023November 3, 2023 by KBD Admin
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) Posted on October 30, 2023November 3, 2023 by KBD Admin
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults Posted on October 19, 2023October 19, 2023 by KBD Admin
